Necla DERELİ, Münire BABAYİĞİT, Filiz KOÇ, Özlem ÖZBEK, Gökhan YILDIZ, Merve KARAŞAHİN, Özge GÜRSÖZLÜ, Nur Sena ÇAKAR

Relationship Between Inflammatory Parameter and Mortality in Intensive Care Patients with COVID-19

We aimed to examine the relationship between hypoxemia, inflammatory parameters, cytokine storm and mortality in the COVID-19 Intensive Care Unit. COVID-19 patients followed in intensive care unit between 21 March and 1 June 2020 were retrospectively analyzed. Inflammatory parameters (CRP, ferritin, D Dimer, leukocyte and lymphocyte, LDH…) were measured in blood samples taken simultaneously. The relationship of these parameters with mortality was evaluated. Of the 30 patients, 11 (36.7%) were female, 19 (63.3%) were male. When living (Group 1) and dead (Group 2) patient groups were compared, a statistically significant difference was found between the groups in terms of mean age (p = 0.013). It was observed that PaO2 / FiO2 ratios were lower in Group 2 in all measurements starting from the day of hospitalization in intensive care. While there was no difference between CRP and procalcitonin values in the first week, the 12th and last day measurements were found to be statistically significantly higher in Group 2 (respectively p2 = 0.050, p2 = 0.016; p2 = 0.050, p2

PDF

___

1. Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 2009; 7: 439-450.
2.https://www.who.int/csr/sars/country/2003_07_11/en/. (Accessed date: 01.03.2021).
3. http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_RA_20140613.pdf WUoM-CTfAtHaIRfA-RGLaoMAf (Accessed date: 01.03.2021).
4. WHO: Middle East respiratory syndrome coronavirus (MERS-CoV). http://www.who.int/emergencies/mers-cov/en/ (Accessed date: 02.03.2021)
5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020 2648.
6. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State JAMA 2020; 323: 1612-1614.
7. 7- Chen G, Zhao J, NingQ. Clinical and immunological features of severe and moderate coronavirus disease 2019 J Clin Invest 2020; 130: 2620-2629.
8. 8- Serebrovska ZO, Chong EY, Serebrovska TV, TumanovsLV,Xi L.Hypoxia, HIF-1α, and COVID-19: from pathogenic factors to potential therapeutic targets Acta Pharmacol Sin 2020; 41: 1539-1546.
9. 9- Lazzeri M, Lanza A, Bellini R, et al. Respiratory physiotherapy in patients with COVID-19 infection in acute setting: a Position Paper of the Italian Association of Respiratory Physiotherapists (ARIR). Monaldi Arch Chest Dis 2020; 90.
10. He G, Han Y, Fang Q, et al. Clinical experience of high-flow nasal cannula oxygen therapy in severe corona virus disease 2019 (COVID-19) patients. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020; 49: 232-239.
11. Xie J, Covassin N,Fan Z, et al. Association Between Hypoxemia and Mortality in Patients With COVID-19 Mayo Clin Proc. n June 2020; 95: 1138-1147.
12. Bahl A, Van Baalen MN,Ortiz L, et al. Early predictors of in hospital mortality in patients with COVID 19 in a large American cohort Internal and Emergency Medicine 2020; 15: 1485-1499.
13. Rahmati L, Moosavi MS. Cytokine-Targeted Therapy in Severely ill COVID-19 Patients: Options and Cautions EJMO 2020; 4: 179-180.
14. Tufan A, Güler AA, Matucci-Cerinic M.COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs Turk J Med Sci 2020; 50: 620-632.
15. 15- Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect 2020; 80: 607-613.
16. 16-Castelli V, Cimini A, Ferri C. Cytokine Storm in COVID-19: "when you come out of thestorm, youwon't be the same person whowalked in". Front Immunol 2020; 11: 2132.
17. 17-Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 2020; 39: 2085-2094.
18. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. ClinImmunol 2020; 215: 108448.
19. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of corona-virus disease 2019 in China. N Engl J Med 2020; 382: 1708-1720.
20. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020; ciaa272.
21. Wang C, Horby P, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020; 395: 470-473
22. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respir-atory distress syndrome and death in patients with coronavirus disease 2019 pneumo-nia in Wuhan, China. JAMA Intern Med 2020; e200994.
23. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-1062.
24. 24- Huang C, Wang Y, Li X, et al. Clinical featrures of patients infected with 2019 novel coronavirus in Wuhan China. Lancet 2020; 395: 497.
25. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descrip tive study. Lancet 2020; 395: 507-513.
26. Du Y, Tu L, Zhu P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study. Am J Respir Crit Care Med 2020; 201: 1372-1379.
27. Celikel Acar B. Cytokine Release Syndrome and Treatment in COVID-19. Turkish J Pediatr Dis 2020; 14: 55-59.